N/A N=49 Use of NAC in Alleviation of Hangover Symptoms
Hangover Symptoms, NAC
Primary: Hangover Symptom Scale — 10; 13; 1; 1 units on a scale — p=0.45
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=294 NAC Inhalation in the Treatment Of Symptomatic acuTe rhinosinUSitis
Acute Rhinosinusitis · Recurrent Acute Rhinosinusitis · Chronic Rhinosinusitis
Primary: Change in the Total Score of the Investigator's Symptomatic Severity Assessment (Day 0, Day 14) — -4.37; -3.56 score on a scale
Phase 2 N=46 N-acetylcysteine in Alcohol Dependence
Alcoholism
Primary: Alcohol Consumption (Percentage of Heavy Drinking Days) — 70.2; 58.4; 20.2; 14.7 percentage of heavy drinking days
Phase 2 N=126 N-Acetylcysteine for Adolescent Alcohol Use Disorder
Alcohol Use Disorder
Primary: Alcohol Use During the Final 4 Weeks of Treatment (Weeks 5 - 8) — 37.9; 42.6 Standard drinks
Early Phase 1 N=14 Influence of n-Acetylcysteine Maintenance on Alcohol Effects
Alcohol Use Disorder
Primary: Number of Alcohol Drinks Chosen — 3.1; 2.8; 3.8 Number of Alcohol Drinks Chosen
Phase 2 N=35 N-acetylcysteine in the Treatment of PTSD and Addiction
PTSD · Addiction
Primary: PTSD Symptoms — 38.7; 52.8; 32.0; 51.5 units on a scale
Phase 2 N=30 N-acetylcysteine Treatment of Alcohol Use Disorder In Veterans With TBI
Traumatic Brain Injury (TBI) · Hazardous and Harmful Alcohol Use
Primary: Change in Percent of Heavy Drinking Days Per Week as Assessed by the Timeline Followback (TFLB) — 26.2; 26.5 change in percent heavy drinking days/wk
Phase 2 N=22 A Randomized Double Blinded Study to Examine the Use of N-acetyl Cysteine for the Prevention and Treatment of HAAF in Patients With Type 1 Diabetes
Type 1 Diabetes · Hypoglycemia Unawareness
Primary: Difference in Epinephrine Secretion During the Morning Episodes of Hypoglycemia on Days One and Two Under the Two Treatment Conditions — 622.8; 867 ug/ml
Phase 2 N=28 N-Acetyl Cysteine Plus Behavioral Therapy for Nicotine Dependent Pathological Gamblers
Gambling · Tobacco Use Disorder
Primary: Yale-Brown Obsessive Compulsive Scale Modified for Pathological Gambling Total Score — 23.5; 20.4 units on a scale
Phase 2 N=111 Effectiveness of N-Acetylcysteine (NAC) in Treating Cocaine Dependent Individuals - 1
Cocaine Dependence
Primary: Number of Participants That Achieved Study Compliance — 22; 15; 18 Participants
Phase 2 N=49 Acamprosate to Reduce Symptoms of Alcohol Withdrawal
Alcohol-Related Disorders · Alcohol Dependence · Alcoholism
Primary: Ratio of Glutamate to Creatine in the Anterior Cingulate of the Brain, Measured on Day 4 — 1.256772; 1.294178 Ratio of glutamate to creatine
Phase 2 N=63 N-Acetyl-Cysteine (NAC) in Early Phase Schizophrenia Spectrum Psychosis
Schizophrenic Psychoses
Primary: Change in Negative Symptoms of Schizophrenia as Measured on the PANSS — 16.9; 17.2 units on a scale — p=0.50
Phase 2 N=35 Neuroscience-Informed Treatment Development for Adolescent Alcohol Use
Alcohol Drinking · Control
Primary: Quantifying the Difference in Glutamate Levels (mmol/kg) During N-Acetylcysteine Versus Placebo in the Anterior Cingulate Brain Region. — 15.7527667; 15.6265229 mmol/kg…
Phase 2 N=90 NAC for Treating Comorbid PTSD and SUD
Posttraumatic Stress Disorder (PTSD) · Alcohol Use Disorder (AUD) · Substance Use Disorder (SUD)
Primary: Change in Alcohol Use Disorder Severity — -2.65; -2.82 drinking days reduction
Phase 2 N=59 Memory and Antioxidants in Vascular Impairment Trial
Vascular Cognitive Impairment no Dementia
Primary: Change in Executive Function — 0.32; 0.36 z-score
Phase 2 N=16 N-acetylcysteine and NMDA Antagonist Interactions
Cognitive Dysfunction
Primary: Target P300 — 2.5; 3.2; 5.2; 3.4 microvolts
Phase 2 N=114 N-acetylcysteine for Tobacco Use Disorder
Nicotine Dependence · Smoking
Primary: Number of Participants With Biochemically-verified Abstinence From Smoking on Days 1-3 of the Protocol. — 8; 6 Participants
Phase 2 N=95 N-acetylcysteine Plus Naltrexone for the Treatment of Alcohol Dependence
Alcoholism
Primary: Percentage of Heavy Drinking Days — 45.0; 50.6; 44.0; 5.2 percentage of heavy drinking days
Phase 4 N=68 Effects of N-acetylcysteine on Low T3 Syndrome
Acute Myocardial Infarction · Euthyroid Sick Syndrome · Ischemic Heart Disease
Primary: Serum T3 Levels at 48 Hours — 93.5; 96.5 ng/dL
Phase 2 N=182 Clinical Trial for Alcohol Use Disorder and Post Traumatic Stress Disorder (PTSD)
Post Traumatic Stress Disorder (PTSD) · Addiction · Alcohol Abuse
Primary: Change in Alcohol Use Severity — -3.406; -3.934 standard drinks per day
Early Phase 1 N=15 n-Acetylcysteine and Cocaine
Cocaine Abuse · Cocaine Dependence
Primary: Number of Times Cocaine Was Selected in the Presence of a Monetary Reward Alternative — 1.0; 0.1; 3.4; 3.9 Number of Cocaine Choices
Phase 3 N=23 Use of N-Acetylcysteine (NAC) in Fingernail Biting
Onychophagia
Primary: Number of Participants Enrolled Within One Year — 12; 11 Participants
Phase 2 N=13 Safety and Efficacy of a Combination Product for the Prevention of Veisalgia
Veisalgia
Primary: Efficacy of Side Effect Prevention Using the Acute Hangover Scale — 6.7; 4.7; 7.8; 6.8 score on a scale
Phase 2 N=8 Repeated-Dose Oral N-acetylcysteine for the Treatment of Parkinson's Disease
Parkinson Disease
Primary: Glutathione (GSH) Brain Levels — 0.93; 0.99 mM
Phase 1 N=24 PP100-01 (Calmangafodipir) for Overdose of Paracetamol
Paracetamol Overdose
Primary: Safety Events — 6; 6; 6; 6 participants
Phase 2 N=45 N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence
Methamphetamine Dependence
Primary: Penn Craving Scale — 24.0; 24.0; 21.1 units on a scale
Phase 2 N=47 N-Acetylcysteine for Neuroprotection in Parkinson's Disease
Parkinson Disease
Primary: Change of Cerebral Glutathione Levels as Measured by Proton Magnetic Resonance Spectroscopy — 3.422; 3.334; 3.745; 4.282 Ratio
Phase 2 N=31 N-acetylcysteine (NAC) for Children With Tourette Syndrome
Tourettes Syndrome · Tic
Primary: Improvement in Tic Severity — 24.3; 21.3 units on a scale
Phase 2 N=70 Study to Evaluate the Efficacy of N-acetylcysteine (NAC) in the Treatment of the Common Cold and Cough
Common Cold Associated With Cough
Primary: Cough Count (Number of Coughs Will be Measured by a 24-hour Ambulatory Cough Monitoring System for the First 72 Hours) — 6.92; 6.51 log-transformed total cough count
Phase 2 N=11 The Role of N-acetyl-l-cysteine (NAC) as an Adjuvant to Opioid Treatment in Patients With Chronic Neuropathic Pain
Neuropathic Pain
Primary: Opioid Use — 101.24; 104.56 morphine equivalent dose